This is a Phase 1 registry record with no posted results; it describes a planned single-dose interventional study in a small sample (n=40) using surrogate endpoints (affect, pain catastrophizing, quantitative sensory testing) to explore mechanistic effects of psilocybin in a novel indication.
Reported
Planned enrollment40
PhasePhase 1
Psilocybin dose (planned)25 mg absolute dose